Stiefel acquires most global rights to Welichem's novel topical NSAID
This article was originally published in Scrip
Executive Summary
Skin care specialist Stiefel, a GlaxoSmithKline company, has paid $35 million up front to acquire WBI-1001, a novel anti-inflammatory agent to treat psoriasis and atopic dermatitis, from Welichem Biotech in Vancouver, Canada.